49,518 Shares in Vaxcyte, Inc. $PCVX Purchased by Edgestream Partners L.P.

Edgestream Partners L.P. purchased a new stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) in the 2nd quarter, Holdings Channel reports. The fund purchased 49,518 shares of the company’s stock, valued at approximately $1,610,000.

A number of other hedge funds have also recently bought and sold shares of the stock. AlphaQuest LLC bought a new stake in shares of Vaxcyte during the 1st quarter worth approximately $33,000. BI Asset Management Fondsmaeglerselskab A S acquired a new position in Vaxcyte during the first quarter worth $35,000. CWM LLC raised its position in Vaxcyte by 197.3% during the second quarter. CWM LLC now owns 1,680 shares of the company’s stock worth $55,000 after acquiring an additional 1,115 shares in the last quarter. Advisors Asset Management Inc. lifted its stake in Vaxcyte by 81.6% in the first quarter. Advisors Asset Management Inc. now owns 1,929 shares of the company’s stock valued at $73,000 after acquiring an additional 867 shares during the last quarter. Finally, Blue Trust Inc. grew its position in shares of Vaxcyte by 176.7% in the 2nd quarter. Blue Trust Inc. now owns 2,161 shares of the company’s stock valued at $70,000 after acquiring an additional 1,380 shares during the period. 96.78% of the stock is currently owned by institutional investors.

Vaxcyte Trading Up 0.9%

Shares of Vaxcyte stock opened at $46.48 on Friday. The company has a 50 day moving average of $44.19 and a 200-day moving average of $37.09. Vaxcyte, Inc. has a 1-year low of $27.66 and a 1-year high of $94.60. The company has a market cap of $6.08 billion, a PE ratio of -9.60 and a beta of 1.28.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($1.56) EPS for the quarter, missing the consensus estimate of ($1.27) by ($0.29). During the same quarter last year, the business posted ($0.83) EPS. Research analysts forecast that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on PCVX shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a report on Tuesday, October 14th. Leerink Partners set a $77.00 price objective on Vaxcyte and gave the company an “outperform” rating in a research report on Wednesday, November 19th. The Goldman Sachs Group started coverage on Vaxcyte in a research note on Friday, September 12th. They set a “neutral” rating and a $38.00 target price for the company. Finally, BTIG Research restated a “buy” rating and issued a $85.00 price target on shares of Vaxcyte in a research note on Monday, November 10th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Vaxcyte presently has a consensus rating of “Moderate Buy” and an average target price of $97.83.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.